Group 1: Bristol Myers Squibb - Bristol Myers Squibb is trading at a forward price-to-earnings (P/E) multiple of just 9, significantly lower than the S&P 500 average of 21 [2] - The company faces challenges such as multiple patent cliffs and a high long-term debt of $47.6 billion, compared to cash and marketable securities of $11.2 billion [3] - Despite risks, the company has secured approvals for two potential blockbuster drugs, Cobenfy and Breyanzi, which could generate substantial revenue [4] - The dividend payout ratio is 60%, supporting a 4% yield, making it attractive for dividend-focused investors [5] Group 2: United Parcel Service (UPS) - UPS has seen a 25% decline in stock price over the past year, resulting in a forward P/E multiple of less than 15 [6] - The company reported a profit of $5.8 billion on revenue of $91.1 billion last year, despite struggles in growth [7] - The payout ratio is around 100%, but free cash flow of $6.2 billion exceeds the $5.4 billion paid out in dividends, indicating a safe payout [8] - UPS offers a high yield of 5.7%, making it appealing for income investors [8] Group 3: Dell Technologies - Dell Technologies trades at a low forward P/E multiple of 10, with significant growth opportunities in artificial intelligence (AI) [9] - The server and networking business reported 54% sales growth in the most recent fiscal year [10] - The stock has a 2.2% dividend yield with a modest payout ratio of 28%, allowing for both dividend payments and growth investments [11]

Core Insights - The article emphasizes the importance of conducting personal in-depth research and due diligence before making investment decisions, highlighting the inherent risks involved in trading [3]. Group 1 - The analysis is intended solely for informational purposes and should not be interpreted as professional investment advice [3]. - There is a clear disclaimer regarding the lack of any stock, option, or derivative positions in the companies mentioned, indicating a neutral stance [2]. - The article expresses the author's personal opinions and does not reflect any business relationships with the companies discussed [2].

Summary of Key Points from the Conference Call Industry Overview - **Industry**: Biopharma in North America - **Market Analysis**: Comprehensive analysis of the US drug market conducted by IQVIA Rx Key Market Metrics - **Total Prescription Year-over-Year (YoY) Growth**: - Latest weekly growth (week ending March 14, 2025) was +4.0%, up from +3.0% the previous week and +2.3% over the past 12 weeks [1][2] - For the week ended March 14, the total market weekly TRx YoY change was +4.0% compared to +1.2% a year ago [2] - Rolling 4-week TRx YoY was +3.1% and rolling 12-week TRx YoY was +2.3% [2] - Extended unit (EUTRx) weekly YoY growth was +2.2%, which is below the TRx YoY growth [2] Company-Specific Insights - **Bristol Myers Squibb (BMY)**: - Cobenfy, approved for schizophrenia on September 26, 2024, had approximately 1,340 scripts for the week, an increase from ~1,300 the previous week [3] - To meet 2025 consensus expectations, Cobenfy TRx needs to track at ~2-3x the volumes from recent schizophrenia launches, with an estimated requirement of ~125K TRx to reach consensus estimates of $160 million [3] - **Vertex Pharmaceuticals (VRTX)**: - Journavx, approved for acute pain on January 30, 2025, recorded ~1,150 scripts for the week, up from ~610 the previous week [4] - To achieve a sales estimate of $87 million, approximately 229K and 441K total scripts are needed for 14-day and 7-day script durations, respectively [4] Competitive Landscape - **Biosimilars**: - Updates on biosimilar launches including Amgen's Wezlana and Teva's Selarsdi, with respective launch dates of January 17, 2025, and February 21, 2025 [5] - **Seasonal Vaccines**: - RSV vaccine volumes are tracking ~65% below last year's levels, while COVID vaccine volumes are also down year-over-year [9] Notable Drug Performance - **Eli Lilly (LLY)**: - Mounjaro and Zepbound launches are being tracked, with Mounjaro showing significant growth [10] - **AbbVie**: - Humira is experiencing a decline of -41% YoY, while Rinvoq and Skyrizi are showing growth rates of 43% and 49% respectively [22][23] Additional Insights - **Market Dynamics**: - The analysis indicates that extended unit data trends were more positive than prescription trends, suggesting a shift towards longer-duration prescriptions [33] - **Sales Trends**: - The IQVIA databases differentiate between prescription and sales trends, with TRx representing total prescriptions dispensed including refills [29] This summary encapsulates the critical insights from the conference call, highlighting the current state of the biopharma industry, specific company performances, and market dynamics.

Core Insights - The article is part of a comparative analysis series focusing on pharmaceutical companies, specifically comparing Pfizer and Johnson & Johnson for investment potential [1] Group 1: Company Analysis - The analysis aims to evaluate which company presents a better investment opportunity for investors [1] Group 2: Research Background - Allka Research has over two decades of experience in investment, specializing in identifying undervalued assets across various sectors including pharmaceuticals [2] - The firm emphasizes a conservative investment approach, aiming to deliver substantial returns and strategic insights to clients [2] - Allka Research seeks to empower investors by simplifying investment strategies and fostering a community of informed investors [2]

Core Viewpoint - The healthcare sector is resilient during economic downturns, making it a favorable environment for solid dividend stocks like Pfizer and Bristol Myers Squibb, which are currently undervalued and present excellent investment opportunities [1][2]. Group 1: Pfizer - Pfizer has faced challenges with declining sales from its coronavirus products and older products losing growth potential, but its forward P/E ratio of 8.9 is significantly lower than the healthcare industry's average of 17.2, indicating it is undervalued [3][6]. - The company has expanded its pipeline significantly, with nearly 60 oncology programs, many in late-stage studies, and plans to launch several blockbuster oncology drugs in the coming years [4][5]. - Pfizer's revenue for 2024 is projected at $63.6 billion, a 7% increase from the previous year, and it offers a forward yield of 6.7%, well above the S&P 500 average of 1.3% [5][6]. Group 2: Bristol Myers Squibb - Bristol Myers Squibb has successfully navigated patent cliffs by developing new products, resulting in a 7% revenue increase to $48.3 billion last year [7][8]. - The company has launched new medicines like Reblozyl, which generates over $1 billion in annual sales, and has a deep pipeline with 50 clinical compounds in development [8][10]. - Bristol Myers offers a forward yield of 4.20% and a forward P/E of 8.9, indicating reasonable valuation and a commitment to raising dividends [11][12].

Core Viewpoint - Bristol Myers Squibb (BMY) is experiencing notable stock performance and is set to report earnings, with significant year-over-year changes anticipated in both earnings per share (EPS) and revenue [2][3]. Company Performance - BMY closed at $60.08, reflecting a +0.3% change from the previous session, while the S&P 500 gained 1.08% [1] - The stock has increased by 10.05% over the past month, outperforming the Medical sector's gain of 0.21% and the S&P 500's loss of 8.26% [1] Earnings Forecast - The upcoming earnings report on April 24, 2025, is expected to show an EPS of $1.55, representing a 135.23% increase from the same quarter last year [2] - Revenue is forecasted at $10.69 billion, which is a decrease of 9.94% from the prior-year quarter [2] Full-Year Estimates - The full-year Zacks Consensus Estimates predict earnings of $6.75 per share and revenue of $45.59 billion, indicating year-over-year changes of +486.96% and -5.6%, respectively [3] Analyst Estimates - Recent adjustments to analyst estimates for BMY reflect short-term business trends, with upward revisions indicating positive sentiment towards the company's operations [4] - The Zacks Rank system, which incorporates these estimate changes, currently ranks BMY as 3 (Hold) [6] Valuation Metrics - BMY is trading with a Forward P/E ratio of 8.88, which is below the industry average of 19.17 [7] - The company has a PEG ratio of 2.22, compared to the industry average PEG ratio of 1.55 [7] Industry Context - BMY operates within the Medical - Biomedical and Genetics industry, which holds a Zacks Industry Rank of 73, placing it in the top 30% of over 250 industries [8]

Group 1 - The article identifies 10 undervalued dividend growth stocks for further research and potential investment, emphasizing their suitability for a dividend growth portfolio [1] - The candidates are ranked based on quality scores, highlighting their high quality and undervaluation [1] - The author, FerdiS, has over 20 years of investment and trading experience, focusing on dividend growth investing and options trading [1] Group 2 - FerdiS manages a portfolio named DivGro, primarily consisting of dividend growth stocks, established in January 2013 [1] - The article mentions collaboration with the founders of Portfolio Insight, an online platform for portfolio management and investment analysis [1] - Dividend Radar is maintained and published as a weekly free spreadsheet of dividend growth stocks [1]

Core Viewpoint - Bristol-Myers Squibb Company (NYSE: BMY) is recommended with a "Buy" rating due to its potential for stock price appreciation despite having high debt levels [1]. Group 1 - The coverage of Bristol-Myers Squibb was initiated in late March 2024 [1]. - The stock is expected to rise, indicating a positive outlook for investors [1]. - The analysis is provided by a chief investment analyst with extensive experience in navigating diverse investment information [1].

Company Performance - Bristol Myers Squibb (BMY) closed at $60.28, reflecting a +0.79% change from the previous trading day's close, outperforming the S&P 500's daily loss of 0.91% [1] - The stock has gained 6.52% over the past month, while the Medical sector lost 1.88% and the S&P 500 lost 7.38% during the same period [1] Earnings Expectations - Analysts expect Bristol Myers Squibb to report earnings of $1.55 per share, indicating a year-over-year growth of 135.23% [2] - The Zacks Consensus Estimate for revenue is projected at $10.69 billion, down 9.94% from the previous year [2] - For the full year, earnings are projected at $6.75 per share, showing a growth of +486.96%, while revenue is expected to be $45.59 billion, reflecting a decrease of -5.6% from the prior year [3] Analyst Estimates and Rankings - Recent modifications to analyst estimates indicate changing business trends, with positive changes suggesting a favorable outlook on the company's health and profitability [4] - The Zacks Rank system, which evaluates estimate changes, currently ranks Bristol Myers Squibb at 3 (Hold) [6] Valuation Metrics - Bristol Myers Squibb has a Forward P/E ratio of 8.86, which is a discount compared to the industry average Forward P/E of 18.77 [7] - The company has a PEG ratio of 2.22, compared to the industry average PEG ratio of 1.51 [8] Industry Context - The Medical - Biomedical and Genetics industry, which includes Bristol Myers Squibb, has a Zacks Industry Rank of 64, placing it in the top 26% of over 250 industries [9]

Core Viewpoint - The article discusses the potential of bispecific antibodies to replace CAR-T therapies in the treatment of multiple myeloma, highlighting insights from Dr. Syed Abbas Ali of Johns Hopkins University [3][4][6]. Group 1: Bispecific Antibodies vs. CAR-T Therapies - Dr. Ali emphasizes that bispecific antibodies, particularly those targeting BCMA and CD3, may surpass CAR-T therapies in efficacy and safety, especially as physicians learn to manage toxicity better [6][7]. - The total response rate for Gilead-Arcellx's Anito-cel is reported at 100%, with lower toxicity compared to Johnson & Johnson's Carvykti, which is primarily used for high-risk patients [4][5]. - The safety profile of Anito-cel shows significant advantages, with a median onset of cytokine release syndrome (CRS) at 2 days and a duration of 3 days, compared to Carvykti's 7 days onset and 4 days duration [5]. Group 2: Market Dynamics and Competitive Landscape - The article notes that Blenrep from GlaxoSmithKline faces challenges in regaining market trust after its previous withdrawal, with analysts expressing concerns over its sales growth potential [8]. - Sanofi's Sarclisa is seen as a competitor to Johnson & Johnson's Darzalex, but the latter's ease of use as a monthly subcutaneous injection poses a significant challenge for Sarclisa [9]. - The article highlights the increasing accessibility of blood component apheresis for CAR-T therapy, which has improved patient treatment options [4].